Ratings Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-09-10 EDT			5-day change	1st Jan Change
875.30 ^DKK	-1.32%		-5.62%	+25.38%

09-10	Health Care Up on Defensive Bias -- Health Care Roundup	DJ
09-10	Weight-loss market to see 16 new drugs by 2029, report estimates	RE

Summary: Novo Nordisk A/S

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
According to Refinitiv, the company's ESG score for its industry is good.

Highlights: Novo Nordisk A/S

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Historically, the company has been releasing figures that are above expectations.

Weaknesses: Novo Nordisk A/S

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 39.05 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings Chart: Novo Nordisk A/S

Source: Surperformance

ESG chart: Novo Nordisk A/S

Source: Refinitiv

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	NOVO NORDISK A/S				582B
	ELI LILLY AND COMPANY				818B
	JOHNSON & JOHNSON				401B
	ABBVIE INC.				347B
	MERCK & CO., INC.				293B
	ASTRAZENECA PLC				258B
	ROCHE HOLDING AG				254B
	NOVARTIS AG				238B
	AMGEN INC.				175B
	PFIZER, INC.				167B
	Average				353.08B
	Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes